Active ingredientFruquintinibCat. No. P-F128-001CAS 1194506-26-7Family · Pharmaceutical analytical standards
Fruquintinib
A highly selective inhibitor of VEGFR 1, 2 and 3, which slows the formation of new blood vessels in tumours; approved in the United States in November 2023 for metastatic colorectal cancer already treated with other therapies. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It was designed to hit only the VEGF receptors: in laboratory tests it did not significantly block any other kinase, whereas many earlier inhibitors hit more than ten.
Go to the active ingredient →Active ingredientFruquintinibCat. No. P-F128-001CAS 1194506-26-7
Isotopically labelledFruquintinib-d6Cat. No. P-F128-002CAS 2978508-76-6
NitrosamineN-Nitroso FruquintinibCat. No. P-F128-004
Impurity4-Chloro-6,7-dimethoxyquinazolineCat. No. P-F128-005CAS 13790-39-1
ImpurityFruquintinib Impurity 1Cat. No. P-F128-006CAS 638217-08-0
ImpurityFruquintinib Impurity 2Cat. No. P-F128-007No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.